Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kim, Yeol Hong | - |
dc.contributor.author | Ryoo, Baek Yeol | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Song, Hong Suk | - |
dc.contributor.author | Kim, Hoon Kyo | - |
dc.contributor.author | Lee, Myung Ah | - |
dc.contributor.author | Im, Seock Ah | - |
dc.contributor.author | Chang, Heung Moon | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Kim, Bong Seog | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.date.accessioned | 2021-09-08T15:41:35Z | - |
dc.date.available | 2021-09-08T15:41:35Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2009-07 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/119711 | - |
dc.description.abstract | Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results. This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m(2) gemcitabine, 100-min infusion, day 1 and 100 mg/m(2) oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR). Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2%, 9.4 and 5.6 months, respectively. Sixteen patients (36.4%) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1%), while the most common hematologic toxicity was anemia (grade 3/4, 6.3%). Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | IN-VITRO | - |
dc.subject | CLINICAL-TRIALS | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | THERAPY | - |
dc.subject | CISPLATIN | - |
dc.subject | RESISTANCE | - |
dc.subject | SURVIVAL | - |
dc.subject | QLQ-C30 | - |
dc.subject | GERCOR | - |
dc.title | Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeol Hong | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.identifier.doi | 10.1007/s00280-008-0873-9 | - |
dc.identifier.scopusid | 2-s2.0-67349175594 | - |
dc.identifier.wosid | 000266495600013 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.64, no.2, pp.317 - 325 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 64 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 317 | - |
dc.citation.endPage | 325 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | QLQ-C30 | - |
dc.subject.keywordPlus | GERCOR | - |
dc.subject.keywordAuthor | Advanced pancreatic cancer | - |
dc.subject.keywordAuthor | Combination chemotherapy | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | GEMOX | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.